Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade ® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study

MLA

Lisa Smits, et al. “Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade ® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study.” Gastroenterology, vol. 154, May 2018, p. S-822. EBSCOhost, https://doi.org/10.1016/s0016-5085(18)32808-7.

APA

Lisa Smits, Lauranne Derikx, Aura van Esch, Joost Drenth, Ronald Boshuizen, Dirk J. De Jong, & Frank Hoentjen. (2018). Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade ® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study. Gastroenterology, 154, S-822. https://doi.org/10.1016/s0016-5085(18)32808-7

Chicago

Lisa Smits, Lauranne Derikx, Aura van Esch, Joost Drenth, Ronald Boshuizen, Dirk J. De Jong, and Frank Hoentjen. 2018. “Mo1844 - Drug Survival and Immunogenicity after Switching from Remicade ® to Biosimilar Ct-P13 in Inflammatory Bowel Disease Patients: Two Year Follow-Up of a Prospective Observational Cohort Study.” Gastroenterology 154 (May): S-822. doi:10.1016/s0016-5085(18)32808-7.